TR201009166A2 - Production method for cefdinir-containing pharmaceutical composition - Google Patents

Production method for cefdinir-containing pharmaceutical composition

Info

Publication number
TR201009166A2
TR201009166A2 TR2010/09166A TR201009166A TR201009166A2 TR 201009166 A2 TR201009166 A2 TR 201009166A2 TR 2010/09166 A TR2010/09166 A TR 2010/09166A TR 201009166 A TR201009166 A TR 201009166A TR 201009166 A2 TR201009166 A2 TR 201009166A2
Authority
TR
Turkey
Prior art keywords
production method
cefdinir
pharmaceutical composition
containing pharmaceutical
preparation
Prior art date
Application number
TR2010/09166A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09166A priority Critical patent/TR201009166A2/en
Priority to PCT/TR2011/000256 priority patent/WO2012060791A2/en
Publication of TR201009166A2 publication Critical patent/TR201009166A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, aktif ajan olarak sefdinir içeren farmasötik dozaj formlarının hazırlanmasında kullanılacak bir üretim yöntemine ilişkindir.The present invention relates to a production method for the preparation of pharmaceutical dosage forms containing cefdinir as the active agent.

TR2010/09166A 2010-11-05 2010-11-05 Production method for cefdinir-containing pharmaceutical composition TR201009166A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2010/09166A TR201009166A2 (en) 2010-11-05 2010-11-05 Production method for cefdinir-containing pharmaceutical composition
PCT/TR2011/000256 WO2012060791A2 (en) 2010-11-05 2011-11-03 Production method for pharmaceutical compositions comprising cefdinir

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09166A TR201009166A2 (en) 2010-11-05 2010-11-05 Production method for cefdinir-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
TR201009166A2 true TR201009166A2 (en) 2012-05-21

Family

ID=45524933

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09166A TR201009166A2 (en) 2010-11-05 2010-11-05 Production method for cefdinir-containing pharmaceutical composition

Country Status (2)

Country Link
TR (1) TR201009166A2 (en)
WO (1) WO2012060791A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935075A (en) * 2012-11-22 2013-02-20 海南三叶美好制药有限公司 Cefdinir capsule and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095313A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising cefdinir

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836918B (en) 1982-09-30 1984-05-30 Fujisawa Pharmaceutical Co 7-substituted-3-vinyl-3-cephem compounds and processes for the production of the same
ATE216887T1 (en) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co TABLETS CONTAINING BETA-LACTAM ANTIBIOTIC AND METHOD FOR THE PRODUCTION THEREOF
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
US20090197855A1 (en) * 2006-05-01 2009-08-06 Makarand Krishnakumar Avachat Pharmaceutical compositions of cefdinir
CN101264085A (en) * 2007-03-14 2008-09-17 南京师范大学 Medicinal composition containing cefdinir cyclodextrin inclusion compound and preparation thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935075A (en) * 2012-11-22 2013-02-20 海南三叶美好制药有限公司 Cefdinir capsule and preparation method thereof
CN102935075B (en) * 2012-11-22 2014-02-19 海南三叶美好制药有限公司 Cefdinir capsule and preparation method thereof

Also Published As

Publication number Publication date
WO2012060791A3 (en) 2012-07-26
WO2012060791A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
EA201300388A1 (en) COMPOUNDS OF SUBSTITUTED BENZAMIDE
EA201270216A1 (en) PHARMACEUTICAL COMPOSITION
MX2011008864A (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products.
IN2014MN02598A (en)
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201270741A1 (en) ORAL COMPOSITIONS AND LIPOPHYL SALTS OF METHylNALTREX
EA201492287A1 (en) DEUTERED DERIVATIVES RUXOLITINIBA
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201690521A1 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
JO3154B1 (en) Trpv4 antagonists
EA201200616A1 (en) DERIVATIVES 2-OXO-1-PIRROLIDININILIMIDAZOTHIAADIA ASOL
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
MX340983B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
TR201009167A2 (en) Pharmaceutical granules containing cephalosporin.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
CO6680629A2 (en) Compounds with antibacterial activity against clsotridium
IN2014DN03245A (en)
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
TR201009166A2 (en) Production method for cefdinir-containing pharmaceutical composition
EA201500313A1 (en) STABILIZED AMORPHOUS FORM OF AGOMELATIN, THE WAY OF ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS, ITS CONTAINING